HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Simplifies, Lowers Fees For Disclosure Challenges In SWIFT Ad Claim Reviews

Executive Summary

National Advertising Division streamlined the process for submitting SWIFT challenges about disclosure claims and lowered the filing fee for the challenges. Growing use of testimonials, “influencer” marketing prompted change.

You may also be interested in...



Cocofloss ‘Whoosh Away Plaque’ Claim Trips On ‘Slippery’ Comparison In Advertising Review

National Advertising Division decision, on challenge by P&G, is another lesson for advertisers not to expect highlighting differences between products establishes theirs as better or more effective than competitors’ products.

NAD Says Fast-Track SWIFT Reviews Doubled Over Past Year

Greater awareness of Fast-Track SWIFT and improved understanding of cases appropriate for the process have nearly doubled the number of SWIFT cases evaluated by the National Advertising Division over the past 12 months, NAD attorney Daniel Range said at the NAD 2022 conference in Washington.

PLx Pharma Irritated By Industry Self-Regulation Group’s Findings On Vazalore GI Comfort Claim

PLx disagrees with National Advertising Division’s recommendations following review on Bayer’s challenge of TV commercial and will appeal findings to National Advertising Review Board. NAD attorneys thank PLx’s “ voluntary participation” in SWIFT review but PLx makes clear it didn’t agree to a SWIFT process.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel